Dosage Forms

Articles

Through the agreement, BARDA will support the advancement of the vaccine candidate to FDA licensure and will handle all late-stage clinical development programs, as well as the scale-up of mRNA-1273 manufacture in 2020.

BARDA Awards Moderna up to $483 Million for COVID-19 Vaccine Candidate Acceleration

Dutch company HALIX has announced it is joining a consortium of partners that are all under the guidance of the University of Oxford to provide good manufacturing practice (GMP) manufacturing services for a COVID-19 vaccine.


HALIX Joins Consortium of Partners to Provide GMP Services for COVID-19 Vaccine

Sanofi and GlaxoSmithKline (GSK) have revealed that they are joining forces to develop an adjuvanted vaccine using their respective technologies that can be used to fight COVID-19.

Sanofi, GSK Collaborate on Adjuvanted Vaccine for COVID-19

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.

Can Vaccine Development Be Safely Accelerated?

In light of the current COVID-19 pandemic, the agencies co-chaired the first global regulators meeting to facilitate development of vaccines against SARS-CoV-2, which causes COVID-19.

FDA, EMA Collaborate on SARS-CoV-2 Vaccine Development

Emergent BioSolutions will help develop and manufacture an oral vaccine candidate and will develop plasma-based antibody therapeutics.

Emergent BioSolutions to Manufacture Oral Vaccine and Develop Antibody Therapeutics for COVID-19

An NIH study of a COVID-19 vaccine is enrolling Seattle-based healthy adult volunteers.

NIH Begins Clinical Trial of Investigational Vaccine For COVID-19

Through the agreement, Emergent will manufacture the vaccine, which is formulated based on Novavax’s proprietary recombinant protein nanoparticle technology platform and its Matrix-M adjuvant to boost immune responses.

Emergent and Novavx Sign Agreement for Experimental COVID-19 Vaccine

WuXi Vaccines, WuXi Biologics’ joint venture with Shanghai Hile Bio-technology, has signed a 20-year vaccine manufacturing contract with a global vaccine leader for $3 billion. 

WuXi Biologics Subsidiary in $3-Billion Vaccine Manufacturing Contract

Sanofi will use a recombinant DNA platform that produces a genetic match to proteins found on the surface of COVID-19 to formulate the vaccine.